menu
    • menu
    [{"orgOrder":0,"company":"Theramex","sponsor":"Dar\u00e9 Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"UNITED KINGDOM","productType":"Hormone","year":"2025","type":"Licensing Agreement","leadProduct":"Etonogestrel","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Theramex","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Theramex \/ Dar\u00e9 Bioscience","highestDevelopmentStatusID":"6","companyTruncated":"Theramex \/ Dar\u00e9 Bioscience"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Newco","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2020","type":"Demerger","leadProduct":"Etonogestrel","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Merck & Co \/ Newco","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Newco"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2021","type":"Demerger","leadProduct":"Etonogestrel","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Merck & Co \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2021","type":"Financing","leadProduct":"Etonogestrel","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Organon \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Merck & Co"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Farmitalia","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"BELGIUM","productType":"Hormone","year":"2020","type":"Licensing Agreement","leadProduct":"Etonogestrel","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal","sponsorNew":"Mithra Pharmaceuticals \/ Farmitalia","highestDevelopmentStatusID":"15","companyTruncated":"Mithra Pharmaceuticals \/ Farmitalia"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Gynial","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"BELGIUM","productType":"Hormone","year":"2020","type":"Licensing Agreement","leadProduct":"Etonogestrel","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal","sponsorNew":"Mithra Pharmaceuticals \/ Gynial","highestDevelopmentStatusID":"15","companyTruncated":"Mithra Pharmaceuticals \/ Gynial"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Zentiva","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"BELGIUM","productType":"Hormone","year":"2020","type":"Agreement","leadProduct":"Etonogestrel","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal","sponsorNew":"Mithra Pharmaceuticals \/ Zentiva","highestDevelopmentStatusID":"15","companyTruncated":"Mithra Pharmaceuticals \/ Zentiva"}]

    Find Clinical Drug Pipeline Developments & Deals for Nexplanon

    Menu

    Nexplanon

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Theramex

                            United Kingdom arrow
                            AACR Annual meeting
                            Not Confirmed

                            Theramex

                            United Kingdom arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etonogestrel

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase I

                            Sponsor : Daré Bioscience

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Dar© Bioscience and Theramex Announce Co-Development for Contraceptive Implant

                            Details : Under the licensing agreement, Dare will develop Casea S (etonogestrel), a potential first-in-category contraceptive candidate for women.

                            Product Name : Casea S

                            Product Type : Hormone

                            Upfront Cash : Undisclosed

                            February 20, 2025

                            Lead Product(s) : Etonogestrel

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase I

                            Sponsor : Daré Bioscience

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Merck & Co

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Merck & Co

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etonogestrel

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Sponsor : Organon

                            Deal Size : Undisclosed

                            Deal Type : Demerger

                            DEALS_DEV arrow-down

                            Merck Announces Completion of Organon & Co. Spinoff

                            Details : Organon will pursue sustainable growth in Women’s Health led by patent-protected Nexplanon (etonogestrel implant) franchise and fueled by its leading contraceptive and fertility businesses. It expects to establish a leading position in Biosimilars focu...

                            Product Name : Nexplanon

                            Product Type : Hormone

                            Upfront Cash : Undisclosed

                            March 06, 2021

                            Lead Product(s) : Etonogestrel

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Sponsor : Organon

                            Deal Size : Undisclosed

                            Deal Type : Demerger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Organon

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Organon

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etonogestrel

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Merck Hosts Organon Investor Day Outlining New Company’s Vision, Focus and Business Model for Sustained Grow...

                            Details : Organon’s commercial strategy will center around Nexplanon (etonogestrel implant), its long-active reversible contraceptive, that delivered approximately $1.6 billion in global sales in 2020.

                            Product Name : Nexplanon

                            Product Type : Hormone

                            Upfront Cash : Undisclosed

                            March 05, 2021

                            Lead Product(s) : Etonogestrel

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Mithra Pharmaceuticals

                            Belgium arrow
                            AACR Annual meeting
                            Not Confirmed

                            Mithra Pharmaceuticals

                            Belgium arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etonogestrel,Ethinyl Estradiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Sponsor : Zentiva

                            Deal Size : $2.2 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Mithra to Commercialize Myring In France, Poland And UK

                            Details : Mithra grants license to Zentiva for commercialization of its vaginal contraceptive ring in three key European markets.

                            Product Name : Myring

                            Product Type : Hormone

                            Upfront Cash : Undisclosed

                            June 07, 2020

                            Lead Product(s) : Etonogestrel,Ethinyl Estradiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Sponsor : Zentiva

                            Deal Size : $2.2 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Mithra Pharmaceuticals

                            Belgium arrow
                            AACR Annual meeting
                            Not Confirmed

                            Mithra Pharmaceuticals

                            Belgium arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etonogestrel,Ethinyl Estradiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Sponsor : Gynial

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Mithra Pharmaceuticals and Gynial Sign Commercialization Agreement for Myring™ in Switzerland

                            Details : Under the terms of this agreement, Gynial will distribute Myring™ in Switzerland, where the Swiss contraceptive rings market is worth EUR 8 million per year.

                            Product Name : Myring

                            Product Type : Hormone

                            Upfront Cash : Undisclosed

                            May 05, 2020

                            Lead Product(s) : Etonogestrel,Ethinyl Estradiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Sponsor : Gynial

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Merck & Co

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Merck & Co

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etonogestrel

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Sponsor : Newco

                            Deal Size : $9.0 million

                            Deal Type : Demerger

                            DEALS_DEV arrow-down

                            Merck to Focus on Key Growth Pillars Through Spinoff of Women’s Health, Trusted Legacy Brands and Biosimilar...

                            Details : Merck will retain its current growth pillars of Oncology, Vaccines, Hospital and Animal Health and continue to invest in research and development of breakthrough innovations across all areas of science.

                            Product Name : Nexplanon

                            Product Type : Hormone

                            Upfront Cash : Undisclosed

                            May 02, 2020

                            Lead Product(s) : Etonogestrel

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Sponsor : Newco

                            Deal Size : $9.0 million

                            Deal Type : Demerger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Mithra Pharmaceuticals

                            Belgium arrow
                            AACR Annual meeting
                            Not Confirmed

                            Mithra Pharmaceuticals

                            Belgium arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etonogestrel,Ethinyl Estradiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Sponsor : Farmitalia

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Mithra Signs LSA for Commercialization of Myring™ in Italy, the Third Biggest Worldwide Market

                            Details : Under the terms of the agreement, Farmitalia will distribute Myring™ in Italy, which is the third largest worldwide vaginal contraceptive ring market in terms of sales value and volume, after the US & Germany.

                            Product Name : Myring

                            Product Type : Hormone

                            Upfront Cash : Undisclosed

                            January 21, 2020

                            Lead Product(s) : Etonogestrel,Ethinyl Estradiol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Sponsor : Farmitalia

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth